SureSelect Cancer Tumor-Specific Assays
SureSelect Cancer Tumor-Specific assays offer genomic profiling for solid tumors from lung, colon, pancreas, kidney, or bladder tissue, to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions/deletions (indels), and translocations (TLs). These small cancer panels enable affordable tumor genomic profiling.
Receive your quote directly from the manufacturer.
Powered by SureSelect XT HS2 library preparation and target enrichment reagents, the assays feature fast hybridization, low sample input, enzymatic fragmentation, and a one-day workflow to generate NGS sequencing-ready libraries. Automation options reduce hands-on time to maximize lab efficiency.
For Research Use Only. Not for use in diagnostic procedures.
- Small cancer panels of approximately 50 genes each for lung, colon, pancreas, bladder, and kidney, based on subsets of gene content from the SureSelect Cancer CGP assay
- Compatibility with low throughput sequencers (Illumina MiSeq and MiniSeq) for lower cost tumor genomic profiling
- Globally curated, clinically relevant biomarker content
- Walkaway convenience using the benchtop Agilent Magnis NGS Prep system with only 15-min hands on time
- For gene fusion detection, modular workflow allows the option to combine a SureSelect Cancer Tumor-Specific DNA assay with the SureSelect Cancer CGP RNA assay (80 genes) together in the same sequencing run
- Start with input as low as 10 ng DNA (recommended 50 ng) to enable profiling of more samples
- Fast hybridization (90 minutes) for library preparation in a single day
- Flexible data analysis options, including Agilent Alissa, customer in-house, and third-party software
Brochures
Tumor genomic profiling with Agilent SureSelect cancer assays
Agilent SureSelect cancer assays are a portfolio of targeted resequencing assays based on next-generation sequencing technology (NGS), which can be utilized in comprehensive genomic profiling (CGP) to advance precision oncology. SureSelect cancer assays enable you to detect key classes of somatic variants and assess immuno-oncology biomarkers and homologous recombination deficiency. Explore the benefits such as error-correcting molecular barcodes, convenient enzymatic fragmentation, and minimum sample input; plus, discover how the workflow solution can be configured to meet the specific needs of your laboratory.
Agilent SureSelect cancer custom panels
Agilent SureSelect Cancer Custom panels enable tumor genomic profiling with next-generation sequencing (NGS) panels customized to fit specific laboratory requirements, including the incorporation of new and emerging biomarkers. SureSelect Cancer Custom panels are combined with library preparation and target enrichment reagents to enable detection of all key classes of somatic changes, including single nucleotide variants (SNVs), copy number variants (CNVs), insertions/ deletions (indels), and translocations (TLs). Agilent Technologies highlights data demonstrating the high target coverage achieved by SureSelect Cancer Custom panels for assays; and their consistent detection of key somatic variant classes.
Agilent SureSelect cancer tumor-specific assays
Agilent SureSelect cancer tumor-specific assays offer genomic profiling of solid tumors with next-generation sequencing (NGS) panels for lung, colon, pancreas, bladder, and kidney. The panels are comprised of DNA modules of approximately 50 genes each for sequencing on Illumina® MiSeq™ and MiniSeq instruments, enabling tumor genomic profiling at a lower cost. Agilent demonstrates the target coverage and distribution uniformity of the assays, their consistent detection of key somatic variant classes, de novo gene fusion detection from just one gene partner, and variant detection from cell-free DNA (cfDNA) samples.
Comprehensive genomic profiling for cancer
Decoding the differences of cancer at a genomic level is key to precision oncology. Agilent's SureSelect Cancer Comprehensive Genomic Profiling (CGP) Assay and workflow detects biomarkers from solid tumors by profiling clinically relevant genes and assessing key classes of mutations to gain insights into tumors. The assay features fast hybridization, low sample input, enzymatic fragmentation, and a one-day workflow to generate NGS sequencing-ready libraries.
